Prevention of myelosuppression and genotoxicity induced by cisplatin in murine bone marrow cells: effect of an organovanadium compound vanadium(III)-l-cysteine

Mutagenesis
Abhishek BasuS Bhattacharya

Abstract

Cisplatin (CDDP) is one of the first-line anticancer drugs indicated for use against various form of human malignancies; but, the therapeutic outcome of CDDP chemotherapy is limited due to the development of myelosuppression and genotoxicity which may lead to secondary cancer. Induction of oxidative stress in normal host cells is thought to be responsible for these adverse effects. Therefore, in search of a potential chemoprotectant, an oraganovanadium compound, viz., vanadium(III)-l-cysteine (VC-III) was evaluated against CDDP-induced clastogenicity and cytotoxicity in bone marrow cells of Swiss albino mice. CDDP was administered intraperitoneally (5mg/kg body weight [b.w.]) and VC-III was given by oral gavage (1mg/kg b.w.) in concomitant and pretreatment schedule. The results showed that VC-III administration significantly (P < 0.001) enhanced cell proliferation and inhibited apoptosis in the bone marrow niche indicating recovery of CDDP-induced myelosuppression. VC-III also significantly (P < 0.001) decreased the percentage of chromosomal aberrations, the frequency of micronuclei formation and the extent of DNA damage. The observed antigenotoxic and cytoprotective effect of VC-III was attributed to its attenuation of free ra...Continue Reading

References

Nov 1, 1992·The Journal of Cell Biology·Y GavrieliS A Ben-Sasson
Nov 5, 1997·Journal of the National Cancer Institute·L B TravisJ D Boice
Apr 25, 2000·Cell Death and Differentiation·F J GeskeL E Gerschenson
Apr 20, 2004·Toxicology Letters·Biswajit MukherjeeMalay Chatterjee
Jul 11, 2006·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Tridib ChakrabortyMalay Chatterjee
Mar 9, 2010·Cancer Letters·Anupam BishayeeMalay Chatterjee
Feb 4, 2011·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·S Abid-EssefiH Bacha
Jan 24, 2012·Journal of Inorganic Biochemistry·Giovana G NunesEmanuel M de Souza
Oct 10, 2012·Future Medicinal Chemistry·Dieter Rehder
Feb 14, 2014·Journal of Biomaterials Applications·Arin BhattacharjeeSudin Bhattacharya
Apr 30, 2014·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Abhishek BasuSudin Bhattacharya

❮ Previous
Next ❯

Citations

Feb 24, 2016·Future Medicinal Chemistry·Dieter Rehder
Apr 12, 2016·Basic & Clinical Pharmacology & Toxicology·Lizhi FengLinlin Lu
Jun 13, 2018·Journal of Cancer Research and Therapeutics·Murat BakirSalim Cerig
Jul 7, 2020·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ericka Francislaine Dias CostaCarmen Silvia Passos Lima
Jul 6, 2019·Anti-cancer Agents in Medicinal Chemistry·Mohsen ChekiAziz Mahmoudzadeh
Oct 12, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew R TrendowskiM Eileen Dolan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry
Abhishek BasuS Bhattacharya
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association
Sonali SinhaAnita Mukherjee
© 2021 Meta ULC. All rights reserved